– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – 83% Reported Grade 3 Adverse Events of Special … [Read more…]
– 92% (n=22/24) of Evaluable Patients Achieved Complete Response (CR) at the Initial 3-Month Timepoint from the Phase 2 Clinical Trial of CG0070, an Oncolytic Immunotherapy, in Combination with KEYTRUDA® (pembrolizumab) for NMIBC Unresponsive to BCG – – Promising Preliminary Efficacy and Safety Data from the Phase 1b/2 study of CG0070 in Combination with OPDIVO® … [Read more…]
CHICAGO–(BUSINESS WIRE)–#AIpowered–Nucleai, an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data, today announced that it will share new data at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in an online publication on an exploratory analysis of a phase … [Read more…]
New preclinical data presented today at the American Diabetes Association’s annual conference suggests that the company’s superabsorbent hydrogel causes changes to the microbiota leading to weight loss and improvements in glucose tolerance and insulin sensitivity BOSTON–(BUSINESS WIRE)–Gelesis (NYSE: GLS), the maker of Plenity for weight management, presented new preclinical data showing weight loss and additional … [Read more…]
Data demonstrate Research Use Only ImPrint test’s ability to identify patients with high risk early breast cancer who may benefit from PD-1/PD-L1 checkpoint inhibition IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a commercial-stage company focused on improving outcomes for breast cancer patients worldwide by providing physicians and patients with next-generation diagnostic and information solutions to inform … [Read more…]
CALQUENCE also maintained efficacy and a sustained safety profile at four years for previously treated patients in ASCEND trial WILMINGTON, Del.–(BUSINESS WIRE)–Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit versus chlorambucil plus obinutuzumab and a safety and tolerability profile consistent with the known … [Read more…]
UPLAND, Calif.–(BUSINESS WIRE)–Friends of Upland Animal Shelter invites the community to participate in its FURst Aid Campaign for medical care donations. With 2,200+ animals on average entering the shelter each year, medical care is one of the shelter’s biggest expenses. Participants in the campaign provide much needed support for surgeries, treatments, spaying and vaccinations of … [Read more…]
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation entitled “Targeting HER2 mutation-positive advanced … [Read more…]
28-month, median follow-up data from the CARTITUDE-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 ASCO Annual meeting Overall response rate remains at 98 percent after more than two years, with median progression-free and overall survival not yet being reached Results from Cohorts A and B of the … [Read more…]
Overall Response Rate (ORR) of 60% Observed in Patients with Relapsed or Refractory (R/R) EBV+ PTLD Consistent with Previously Reported Studies Completion of All Pre-Approval Inspections Required to Support EU Marketing Authorization Application; Anticipated European Commission Approval On-Track for Q4 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, … [Read more…]
